Staňte se členy

Odkazy a zdroje - Studie - PROSPER



PROSPER

Prospective Study of Pravastatin in the Elderly at Risk

Author(s)
(a)Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen ELEM, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RGJ, Twomey C, Stott DJ
(b) Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RGJ

Title(s)
(a) The design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
(b) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Reference(s)
(a) Am J Cardiol 1999;84:1192–7
(b) Lancet 2002;360:1623–30

Disease
Cardiovascular disease

Purpose
To test whether pravastatin reduces the risk of vascular events in elderly people with pre-existing vascular disease or at high risk of its development

Study design
Randomised, double-blind, placebo-controlled

Follow-up
Mean 3.2 years

Patients
5804 individuals (2891 pravastatin, 2913 placebo), mean age 75 years, with either pre-existing vascular disease or raised risk due to smoking, hypertension or diabetes, and with total cholesterol 4.0–9.0 mmol/l and triglycerides < 6.0 mmol/l

Treatment regimen
Pravastatin, 40 mg/day, or placebo

Concomitant therapy
Diet to provide < 30% of total calories from fat (< 10% as saturated fat) and cholesterol intake of < 300 mg/day

Results
Pravastatin reduced the incidence of the primary composite endpoint of death from coronary heart disease, nonfatal MI and fatal or nonfatal stroke to 14.1% compared to 16.2% with placebo (hazard ratio 0.85, 95% CI 0.74–0.97; p = 0.014)